ライフサイエンスコーパス: noninferior

1 The noninferior accuracy for diagnosis of distant metastasis

2 Antibody responses in girls were noninferior after 2 doses vs 3 doses for all 4 vaccine g

3 tudy explored whether antibody responses are noninferior after 2 versus 3 doses in girls.

4 TAVR was a noninferior alternative to surgery in patients with seve

5 DEVICE is a reasonable noninferior alternative to warfarin for stroke preventio

6 nicotine-replacement therapy among women and noninferior among men.

7 according to a T&E regimen was statistically noninferior and clinically comparable with a monthly reg

8 All aflibercept groups were noninferior and clinically equivalent to monthly ranibiz

9 endamustine-rituximab was demonstrated to be noninferior and less toxic to R-CHOP and should be consi

10 and dabigatran (an antithrombin agent) were noninferior and probably safer than conventional anticoa

11 This rate was noninferior and superior to the historical control rate.

12 The 200-mg regimen was noninferior, and the 300-mg regimen was superior, to eno

13 patients with STEMI, prasugrel showed to be noninferior as compared with ticagrelor in terms of resi

14 cal power to assess whether lixisenatide was noninferior as well as superior to placebo, as defined b

15 Reader accuracy with IC-IR was noninferior at 50% (100 mAs [effective]) and 25% (300 mA

16 In the randomized comparison, PG-2 was noninferior but not superior to PG-1 for percentage of o

17 VR through week 48, switching to FTC/TDF was noninferior compared to continued 3TC/ABC (86.4% vs 83.3

18 arge vessel stenting, BP-DES appeared barely noninferior compared with DP-DES and more effective than

19 using stage 1 results was confirmed to have noninferior Ctrough levels relative to IV rituximab 375

20 n model, a 25% exposure reduction maintained noninferior diagnostic accuracy.

21 f CPR skill retention, VO training yielded a noninferior difference in CC rate compared with VSI trai

22 ted liver scans, lower-dose ANLM images were noninferior (difference: +0.015 [95% CI: -0.077, 0.106])

23 lower-dose ANLM versus routine-dose FBP were noninferior (difference: -0.041 [95% CI: -0.090, 0.009]

24 rest/stress SPECT-MPI (n=81), CCTA/rCTP had noninferior discriminatory value to CCTA/SPECT-MPI (area

25 ntrations (GMCs) for vaccine types were only noninferior for 2 versus 3 doses for HPV-18 (at 2-3 year

26 GMCs for HPV-16/18 were not noninferior for 2 versus 3 doses, except for HPV-18 (at

27 girls (2 doses) to women (3 doses) remained noninferior for all genotypes to 36 months.

28 The GMT ratios were noninferior for girls (2 doses) to girls (3 doses): 0.95

29 The GMT ratios were noninferior for girls (2 doses) to women (3 doses): 2.07

30 in the standard group (P = 0.0004), and was noninferior for neutrophil gelatinase-associated lipocal

31 n with missed adenomas greater than 5 mm was noninferior for segments with BBPS scores of 2 (5.2%) vs

32 We postulated that the miss rate was noninferior for segments with BBPS scores of 2 vs those

33 ate from baseline to month 6 (Nankivell) was noninferior for TacHexal versus Prograf using observed v

34 (HPV-16/18/31/33/45), the avidity index was noninferior for the 2-dose compared with the 3-dose sche

35 biodegradable polymer-based O-SES was found noninferior for the primary end point in-stent late lume

36 ivered on 3 alternative dosing schedules was noninferior for types 6, 11, 16, and 18 at 32 months pos

37 ed with up-titration of glargine resulted in noninferior HbA1c levels, with secondary analyses indica

38 Miltefosine was noninferior if the proportion of treatment failures was

39 ipants, humoral immune response to HZ/su was noninferior in HZ-PreVac compared with HZ-NonVac (adjust

40 standard nucleoside backbone was shown to be noninferior or superior to first-line regimens containin

41 To determine whether insulin degludec is noninferior or superior to insulin glargine U100 in redu

42 ration paclitaxel-eluting stent (PES) and is noninferior or superior to the sirolimus-eluting stent (

43 Aspirin was noninferior (P < 0.001) but not superior (P = 0.22) to d

44 The T&E regimen was noninferior (P < 0.001) to the monthly regimen, with a l

45 for surgical residents were associated with noninferior patient outcomes and no significant differen

46 By intention-to-treat BP-DES were noninferior (predefined margin, 3.80%) compared with DP-

47 NSAID use resulted in noninferior rates of pleurodesis efficacy at 3 months.

48 The ABSORB III trial demonstrated noninferior rates of target lesion failure (cardiac deat

49 However, Group 1 achieved a noninferior resolution of amblyopia (mean final VA 0.18

50 HAP, treatment with GDP is associated with a noninferior response rate, similar transplantation rate,

51 The objective was to demonstrate noninferior rituximab Ctrough of SC rituximab relative t

52 10, a randomized clinical trial demonstrated noninferior survival for patients with advanced ovarian

53 unavir/ritonavir and lamivudine demonstrated noninferior therapeutic efficacy and similar tolerabilit

54 eding events based on not having crossed the noninferior threshold of 5%.

55 strategy of left atrial appendage closure is noninferior to "systemic" anticoagulation with warfarin.

56 Our data suggest that (18)F-DCFPyL is noninferior to (68)Ga-PSMA-HBED-CC, while offering the a

57 usion: Our data suggest that (18)F-DCFPyL is noninferior to (68)Ga-PSMA-HBED-CC, while offering the a

58 nibizumab resulted in visual acuity that was noninferior to (not worse than) PRP treatment at 2 years

59 zolid phosphate (plus 4 days of placebo) was noninferior to 10 days of 600-mg twice-daily oral linezo

60 id (200 mg once daily) has been proven to be noninferior to 10 days of linezolid (600 mg twice daily)

61 nogram-affirmed iterative reconstruction was noninferior to 100% exposure (P = .002 and P < .001, res

62 s, 3 months of dual antiplatelet therapy was noninferior to 12 months for NACCE, without significantl

63 treatment with systemic glucocorticoids was noninferior to 14-day treatment with regard to reexacerb

64 elet treatment with DAPT for 6 months may be noninferior to 24-month DAPT in aspirin-sensitive patien

65 in women aged 15-25 years and 2D (M0,12) was noninferior to 2D (M0,6).

66 After BEACOPPbaseline, 20 Gy IF-RT was noninferior to 30 Gy (10-year PFS, 84% v 84%; HR, 1.0; 9

67 th 2D regimens in girls aged 9-14 years were noninferior to 3D in women aged 15-25 years and 2D (M0,1

68 licited HPV-16/18 immune responses that were noninferior to 3D in women aged 15-25 years.

69 A single 1200-mg dose of oritavancin was noninferior to 7-10 days of vancomycin in treating ABSSS

70 f once-weekly rifapentine plus isoniazid was noninferior to 9 months of isoniazid alone for preventin

71 Dalbavancin delivered as a single dose was noninferior to a 2-dose regimen (81.4% vs 84.2%; differe

72 A single 1500-mg infusion of dalbavancin is noninferior to a 2-dose regimen, has a similar safety pr

73 orbable scaffold has been demonstrated to be noninferior to a contemporary metallic drug-eluting sten

74 ith about 5 hours of therapeutic contact was noninferior to a conventional course of CBT that provide

75 strategy regarding red-cell transfusion was noninferior to a liberal strategy with respect to the co

76 rom baseline (letters) with brolucizumab was noninferior to aflibercept at week 12 (5.75 and 6.89, re

77 To investigate whether bevacizumab is noninferior to aflibercept for the treatment of macular

78 vein occlusion, intravitreal bevacizumab was noninferior to aflibercept with respect to visual acuity

79 less than 1.3 indicating that SLND alone is noninferior to ALND.

80 rdial, centrifugal-flow LVAD was found to be noninferior to an axial-flow LVAD with respect to surviv

81 an iFR-guided revascularization strategy was noninferior to an FFR-guided revascularization strategy

82 ded prophylaxis for 28 days with aspirin was noninferior to and as safe as dalteparin for the prevent

83 TRAV was considered noninferior to BIM if the upper limit of the 95% CI of t

84 High-dose unilateral ECT was noninferior to bitemporal ECT regarding the 24-item HAM-

85 t forgoing bridging anticoagulation would be noninferior to bridging with low-molecular-weight hepari

86 ment, PCI with everolimus-eluting stents was noninferior to CABG with respect to the rate of the comp

87 Trials concluding IAD is noninferior to CAD were based on wide NIMs that included

88 Tests of noninferiority showed that TCC was noninferior to CBT-I at 15 months ( P = .02) and at mont

89 Here, we evaluated whether TCC is noninferior to CBT-I for the treatment of insomnia in su

90 nt meditation, was found to be statistically noninferior to CBT-I, the gold standard for behavioral t

91 CCTA/rCTP is noninferior to CCTA/SPECT-MPI to discriminate ACS and pr

92 acic echocardiography and lung ultrasound is noninferior to chest radiograph when used to accurately

93 cic echocardiography and lung ultrasound are noninferior to chest x-ray for screening of pneumothorax

94 is not available leads to outcomes that are noninferior to CIC follow-up.

95 Etelcalcetide was noninferior to cinacalcet on the primary end point.

96 The hypothesis that cefpodoxime would be noninferior to ciprofloxacin by a 10% margin (ie, for th

97 mindfulness-based stress reduction (MBSR) is noninferior to cognitive behavioral therapy for insomnia

98 The short-course radiotherapy was noninferior to commonly used radiotherapy.

99 ioned, continuous-flow, centrifugal pump was noninferior to contemporaneously implanted, commercially

100 Intermittent androgen deprivation was noninferior to continuous therapy with respect to overal

101 e to assess whether intermittent therapy was noninferior to continuous therapy with respect to surviv

102 t prescribing in the DEV and IMCP groups was noninferior to control (mean percentage point difference

103 trial, we tested whether dexmedetomidine was noninferior to control with respect to proportion of tim

104 symptomatic VTE, NOACs have been shown to be noninferior to conventional anticoagulant therapy for pr

105 nd specificity of CellScope-based LED FM was noninferior to conventional LED FM by using a preselecte

106 Filtered sunlight was noninferior to conventional phototherapy for the treatme

107 Apixaban was noninferior to conventional therapy (P<0.001) for predef

108 A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of

109 o achieve noninferiority at 6 months but was noninferior to CPVI at 1 year in achieving freedom of AF

110 le procedure but, after redo procedures, was noninferior to CPVI at 12 months for freedom from AF and

111 o randomized trials revealed rituximab to be noninferior to cyclophosphamide for inducing remission i

112 and at both starting doses, peginesatide was noninferior to darbepoetin in increasing and maintaining

113 rior cell grades for both XG-102 groups were noninferior to dexamethasone (-0.054 anterior cell grade

114 on of XG-102 at the end of ocular surgery is noninferior to dexamethasone eye drops in the treatment

115 f-administered therapy without reminders was noninferior to direct observation in the United States;

116 mer sirolimus-eluting stents (BP-SES) proved noninferior to durable polymer everolimus-eluting stents

117 ed these 2 stents and has shown that ZES was noninferior to EES at 12-month for the primary end point

118 ne expression profiling (GEP) blood test was noninferior to EMB between 6 and 60 months post transpla

119 Stenting was noninferior to endarterectomy with regard to the primary

120 isk for surgical complications, stenting was noninferior to endarterectomy with regard to the rate of

121 cutely ill medical patients, rivaroxaban was noninferior to enoxaparin for standard-duration thrombop

122 D 1 and 725 from EMERALD 2, peginesatide was noninferior to epoetin in maintaining hemoglobin levels

123 nd methotrexate, P=0.26); triple therapy was noninferior to etanercept and methotrexate, since the 95

124 ydroxychloroquine added to methotrexate, was noninferior to etanercept plus methotrexate in patients

125 Therapies) trial found triple therapy to be noninferior to etanercept-methotrexate in patients with

126 clitaxel-eluting stents were not shown to be noninferior to everolimus-eluting stents, and they resul

127 n a phase 3 trial, telaprevir twice daily is noninferior to every 8 hours in producing SVR12, with si

128 uction at 25% and 50% exposure reduction was noninferior to FBP at 100% exposure (P </= .013).

129 sing mixed linear models showed that PBT was noninferior to FBT on all outcomes at 6-, 12-, and 18-mo

130 Although withholding FDP was found to be noninferior to FDP for the study population as a whole (

131 Withholding FDP was noninferior to FDP in holes </=400 mum in diameter.

132 We aimed to evaluate whether iFR is noninferior to FFR with respect to the rate of subsequen

133 risk for cardiovascular events, degludec was noninferior to glargine with respect to the incidence of

134 a mean follow-up of 2.3 years, Respimat was noninferior to HandiHaler with respect to the risk of de

135 ily after initial treatment with heparin was noninferior to high-quality standard therapy and caused

136 At moderate doses, celecoxib was found to be noninferior to ibuprofen or naproxen with regard to card

137 effectiveness of home-based HT with a CD is noninferior to iHT performed by therapists in pediatric

138 Therapy (ENCORE), at 1 year, eliglustat was noninferior to imiglucerase enzyme therapy in maintainin

139 e 1-year follow-up, telephone counseling was noninferior to in-person counseling for all psychosocial

140 e delivery of BRCA1/2 genetic counseling was noninferior to in-person delivery.

141 hypothesis that intramuscular midazolam was noninferior to intravenous lorazepam by a margin of 10 p

142 Intravenous-to-oral solithromycin was noninferior to intravenous-to-oral moxifloxacin.

143 o assess whether intravitreal bevacizumab is noninferior to intravitreal aflibercept for treatment of

144 o assess whether intravitreal bevacizumab is noninferior to intravitreal aflibercept for treatment of

145 Daily CMX was not noninferior to IPT-SP for preventing maternal malaria bu

146 ted evidence that the Watchman device may be noninferior to long-term OAC in selected patients.

147 1, a left atrial appendage closure device is noninferior to long-term warfarin for stroke prevention.

148 Sulfur hexafluoride gas was found to be noninferior to longer-acting gases (95% confidence inter

149 Sulfur hexafluoride gas tamponade was noninferior to longer-acting gases in the surgical manag

150 t femoral hemostasis achieved through VCD is noninferior to manual compression in terms of vascular a

151 transfemoral coronary angiography, VCDs were noninferior to manual compression in terms of vascular a

152 Pyronaridine-artesunate was noninferior to mefloquine plus artesunate for the primar

153 Miltefosine is noninferior to meglumine antimoniate for treatment of pe

154 Ceftazidime-avibactam plus metronidazole was noninferior to meropenem across all primary analysis pop

155 eftolozane/tazobactam plus metronidazole was noninferior to meropenem in adult patients with cIAI, in

156 eftolozane/tazobactam plus metronidazole was noninferior to meropenem in the primary (83.0% [323/389]

157 Ceftazidime-avibactam plus metronidazole was noninferior to meropenem in the treatment of complicated

158 Everolimus 1.5 mg was noninferior to MMF for this endpoint at month 12 (35.1%

159 ce for as-needed ranibizumab injections, was noninferior to monthly ranibizumab as well as to as-need

160 that monthly and bimonthly aflibercept were noninferior to monthly ranibizumab at preventing vision

161 n eyes with PVD, and quarterly treatment was noninferior to monthly treatment (P = 0.001).

162 that zoledronic acid (ZA) every 3 months was noninferior to monthly ZA in reducing the risks of SREs.

163 Glycerol phenylbutyrate was noninferior to NaPBA with respect to ammonia control in

164 whether HHHFNC provides respiratory support noninferior to nasal continuous positive airway pressure

165 The use of HHHFNC was noninferior to nCPAP with regard to the primary outcome:

166 -12% (P<0.001 that same-day discharge is not noninferior to next-day discharge).

167 t if high-flow conditioned oxygen therapy is noninferior to NIV for preventing postextubation respira

168 10-mg daily doses of ulipristal acetate were noninferior to once-monthly leuprolide acetate in contro

169 omy to date, and it demonstrates that RPD is noninferior to OPD in terms of pancreatic fistula develo

170 Robotic pancreatoduodenectomy was also noninferior to OPD in terms of the occurrence of any com

171 monstrated that high flow nasal cannulae are noninferior to or no better than CPAP when used to suppo

172 ith sentinel lymph node dissection alone was noninferior to overall survival for those treated with a

173 ospitals without on-site cardiac surgery was noninferior to PCI performed at hospitals with on-site c

174 ymptom monitoring without PEP was considered noninferior to PEP after pertussis exposure if the lower

175 edure, forgoing bridging anticoagulation was noninferior to perioperative bridging with low-molecular

176 e-photon emission tomography was found to be noninferior to PET in terms of specificity (P < .001) bu

177 was hypothesized that PF tafluprost would be noninferior to PF timolol over 12 weeks with regard to c

178 Sitagliptin was noninferior to placebo for the primary composite cardiov

179 We hypothesized that semaglutide would be noninferior to placebo for the primary outcome.

180 The DPP4i sitagliptin has been shown to be noninferior to placebo with regard to primary and second

181 ary hypothesis was that liraglutide would be noninferior to placebo with regard to the primary outcom

182 hat exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 f

183 xenatide, administered once weekly, would be noninferior to placebo with respect to safety and superi

184 To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 a

185 Primary analyses examined whether 4F-PCC was noninferior to plasma for the coprimary end points of 24

186 g in low-body-weight (LBW) patients would be noninferior to prasugrel 10 mg in higher-body-weight (HB

187 chemotherapy and interval cytoreduction are noninferior to primary cytoreduction and adjuvant chemot

188 setts without on-site surgical services were noninferior to procedures performed at hospitals with on

189 To determine whether yoga is noninferior to PT for cLBP.

190 alized yoga program for nonspecific cLBP was noninferior to PT for function and pain.

191 BR was noninferior to R-CHOP/R-CVP, as assessed by the primary

192 o determine whether cryoballoon ablation was noninferior to radiofrequency ablation in symptomatic pa

193 s randomized trial, cryoballoon ablation was noninferior to radiofrequency ablation with respect to e

194 n the per protocol analysis, bevacizumab was noninferior to ranibizumab (bevacizumab minus ranibizuma

195 Bevacizumab was noninferior to ranibizumab for visual acuity at 1 year w

196 Ranibizumab with laser was noninferior to ranibizumab monotherapy (mean average BCV

197 safety and efficacy of VGLB ablation proved noninferior to RFA for the treatment of paroxysmal AF.

198 s to routine vaccines given with 4CMenB were noninferior to routine vaccines alone for all antigens,

199 -dose FBP images without ANLM or SAFIRE were noninferior to routine-dose images for abdominal CT but

200 COBI was noninferior to RTV in combination with ATV plus FTC/TDF

201 icenter AMI trial, second-generation EES was noninferior to SES, and superiority for MACE was suggest

202 vir-velpatasvir-voxilaprevir for 8 weeks was noninferior to sofosbuvir-velpatasvir for 12 weeks, but

203 Primary care management was noninferior to specialist management with a mean change

204 -dose intravenous fosaprepitant (150 mg) was noninferior to standard 3-day oral aprepitant in prevent

205 Micafungin was noninferior to standard care as antifungal prophylaxis i

206 vitamin K oral anticoagulants, were at least noninferior to standard care in the prevention of most p

207 Low dose is noninferior to standard dose with respect to rate of blo

208 Rivaroxaban was noninferior to standard therapy (noninferiority margin,

209 fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long

210 These data indicate BR is noninferior to standard therapy with regard to clinical

211 In conclusion, rituximab was noninferior to steroids for the treatment of juvenile SD

212 r sites in Italy tested whether rituximab is noninferior to steroids in maintaining remission in juve

213 l treatment with beta-lactam monotherapy was noninferior to strategies with a beta-lactam-macrolide c

214 Oral edoxaban was noninferior to subcutaneous dalteparin with respect to t

215 Pazopanib was noninferior to sunitinib with respect to progression-fre

216 is superior to standard medical therapy and noninferior to surgical aortic valve replacement for 1-y

217 4.9% to 12.0%), so telaprevir twice daily is noninferior to telaprevir every 8 hours.

218 y response to HPV-6, 11, 16, and 18 that was noninferior to that generated by the qHPV vaccine.

219 enhanced CT has a breakthrough reaction rate noninferior to that of a 13-hour oral premedication regi

220 aterial-enhanced computed tomography (CT) is noninferior to that of a traditional 13-hour oral regime

221 y IOP-lowering efficacy of BAK-free TRAV was noninferior to that of BAK 0.02%-preserved BIM; both red

222 rneal donor tissue preserved 8 to 14 days is noninferior to that of donor tissue preserved 7 days or

223 ography with FBP and SAFIRE is statistically noninferior to that of full-dose CT enterography for act

224 The rate of response in group 2 was noninferior to that of group 1.

225 The EFS for SR patients in AAML0631 was noninferior to that of patients in the AIDA 0493 histori

226 The IOP-lowering effect of PF tafluprost was noninferior to that of PF timolol.

227 found that the efficacy of isavuconazole was noninferior to that of voriconazole.

228 out axillary lymph node dissection (ALND) is noninferior to that of women treated with axillary disse

229 confidence interval: 0.8%, 5.7%), which was noninferior to the 2.1% (13 of 626 patients; 95% confide

230 oth 2-dose schedules in young girls remained noninferior to the 3-dose schedule in women up to study

231 the 2D_M0,6 and 2D_M0,12 schedules remained noninferior to the 3D_M0,1,6 schedule in terms of seroco

232 62.1% treatment success in the CD group was noninferior to the 71.0% in the iHT group (difference, -

233 y LTA for prasugrel 5 mg in LBW patients was noninferior to the 75th percentile for prasugrel 10 mg i

234 hin-strut sirolimus-eluting Orsiro stent was noninferior to the biolimus-eluting Nobori stent in unse

235 in the extended-release naltrexone group was noninferior to the buprenorphine-naloxone group (differe

236 utcomes of patients followed in the TMVC are noninferior to the CIC.

237 with ceftaroline fosamil was observed to be noninferior to the comparator agents (ceftriaxone for CA

238 The 4-month regimen was not noninferior to the control regimen.

239 very 12 weeks regimen of zoledronic acid was noninferior to the every 4 weeks regimen for the proport

240 .908; SAFIRE 3, 0.935; SAFIRE 4, 0.924) were noninferior to the mean AUC with full-dose FBP scans (0.

241 The rate of MACCE (7.3%) was noninferior to the performance goal (18.3%, pnoninferior

242 The respiratory polygraphy protocol was noninferior to the polysomnography protocol based on the

243 blind randomized trial, a novel PtCr-EES was noninferior to the predicate CoCr-EES for TLF, with nons

244 d 2 each had high rates of SVR12, which were noninferior to the reported rate of response to the comb

245 ree lower-dose alternatives were found to be noninferior to the routine-dose FBP.

246 with telaprevir for the first 12 weeks, was noninferior to the same regimen for 48 weeks in patients

247 N1) during 2012-2013 (the HD formulation was noninferior to the SD formulation for influenza A[H1N1]

248 ts with coronary artery disease, the EES was noninferior to the SES at 9 months.

249 At 2-year follow-up, the EES was found to be noninferior to the SES with regard to both patient-relat

250 The everolimus-eluting stent was found to be noninferior to the sirolimus-eluting stent.

251 The drug-coated balloon was noninferior to the standard balloon with respect to safe

252 essment of LV function with SSIR at 3.0 T is noninferior to the standard of reference irrespective of

253 s; 0, 6, 12 months; or 0, 12, 24 months) are noninferior to the standard schedule at >2 years after i

254 rative urine output target of 0.2 mL/kg/h is noninferior to the standard target of 0.5 mL/kg/h and re

255 QIV was noninferior to the TIVs for shared strains (A/H3N2 and A

256 The use of high-flow nasal cannulae was noninferior to the use of nasal CPAP, with treatment fai

257 We hypothesized that VO training would be noninferior to the VSI approach with respect to chest co

258 wn that antibody responses after 2 doses are noninferior to those after 3 doses, suggesting that 2 an

259 nd HPV-18 one month after the last dose were noninferior to those among young women who received 3 do

260 Diagnoses from WSI were noninferior to those from TM.

261 body responses to HPV-6, 11, 16, and 18 were noninferior to those generated by the qHPV vaccine.

262 OCKET-1, post hoc outcome measure). was also noninferior to timolol (ROCKET-2).

263 LBN 0.024% QD in the evening was noninferior to timolol 0.5% BID over 3 months of treatme

264 hat mean IOP reduction with LBN was not only noninferior to timolol but significantly greater (P </=

265 ine intraocular pressure (P < .001), and was noninferior to timolol in the per-protocol population wi

266 A single dose of oritavancin was noninferior to twice-daily vancomycin administered for 7

267 TC was noninferior to UC on all primary outcomes.

268 rials (003 and 004) showed fidaxomicin to be noninferior to vancomycin for curing Clostridium diffici

269 In 2 phase 3 clinical trials, telavancin was noninferior to vancomycin in patients with HAP due to gr

270 It has been found to be noninferior to vancomycin; however, its cost-effectivene

271 WC2031 was noninferior to Vibramycin for uncomplicated urogenital c

272 Individually, NOACs were at least noninferior to vitamin K antagonists, but a clear superi

273 have been developed and found to be at least noninferior to VKAs with regard to efficacy, but the ris

274 In this trial, LAA occlusion was noninferior to warfarin for ischemic stroke prevention o

275 Rivaroxaban is noninferior to warfarin for preventing stroke in atrial

276 jor bleeding; and rivaroxaban 20 mg Q.D. was noninferior to warfarin for stroke and systemic embolism

277 closure with a filter device (Watchman) was noninferior to warfarin for stroke prevention in atrial

278 ), left atrial appendage (LAA) occlusion was noninferior to warfarin for stroke prevention, but a per

279 al Fibrillation (ROCKET AF), rivaroxaban was noninferior to warfarin for the prevention of stroke and

280 ts with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or

281 esigned to determine whether rivaroxaban was noninferior to warfarin for the primary end point of str

282 rior and dabigatran etexilate 110 mg BID was noninferior to warfarin in preventing stroke and systemi

283 randomized, clinical trial, rivaroxaban was noninferior to warfarin in preventing stroke or systemic

284 on 48), the factor Xa inhibitor edoxaban was noninferior to warfarin in preventing stroke or systemic

285 Dabigatran etexilate 110 mg BID was noninferior to warfarin in reducing stroke and systemic

286 The oral factor Xa inhibitor rivaroxaban was noninferior to warfarin in the Rivaroxaban Once Daily, O

287 met the primary efficacy end point of being noninferior to warfarin therapy for the prevention of st

288 oston Scientific, Natick, Massachusetts) was noninferior to warfarin therapy.

289 Edoxaban was noninferior to warfarin with respect to the primary effi

290 r Xa inhibitor with 50% renal clearance, was noninferior to well-managed warfarin for stroke or syste

291 O-SES was noninferior to X-EES for the primary end point (0.10+/-0

292 Resolute ZES were noninferior to Xience V EES in treating "real-world" pat

293 Denosumab was noninferior to ZA in delaying time to first on-study SRE

294 ledronic acid administered every 12 weeks is noninferior to zoledronic acid administered every 4 week

295 e whether zoledronic acid every 12 weeks was noninferior to zoledronic acid every 4 weeks in patients

296 of children was comparable to (specifically, noninferior to) annual treatment of the entire community

297 Tedizolid phosphate was a statistically noninferior treatment to linezolid in early clinical res

298 Denosumab was noninferior (trending to superiority) to ZA in preventin

299 This end point was noninferior using a 20% margin and a 95% confidence inte

300 n a hierarchical testing procedure, TAVR was noninferior with respect to echocardiographic indexes of